Latest news
Outcome of 'Zeus' Trial Throws Wrench in Heart Disease Theory - NewserNewser · Sat, 08 Aug 2026 11:30:00 GMTNew heart drug targeting inflammation falls short in clinical trial - Cardiovascular BusinessCardiovascular Business · Thu, 06 Aug 2026 20:22:24 GMTNovo Nordisk Q2'26: ZEUS failure overshadows obesity pipeline advances - AllSciAllSci · Thu, 06 Aug 2026 11:38:14 GMTNovo Nordisk (NYSE:NVO) Stock May Be Below Fair Value On ZEUS Trial Fallout - simplywall.stsimplywall.st · Wed, 05 Aug 2026 20:01:11 GMTZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients - TCTMD.comTCTMD.com · Mon, 03 Aug 2026 17:05:08 GMTNovo Nordisk's Oral Weight-Loss Pill Faces Its Moment of Truth Amid Trial Setback and Lilly Legal Fi - AD HOC NEWSAD HOC NEWS · Mon, 03 Aug 2026 13:02:08 GMTNovo’s late-stage IL-6 stumble shakes inflammation space - BioSpaceBioSpace · Mon, 03 Aug 2026 11:36:04 GMTWeekly Recap: ZEUS miss lifts BGE-102 and Analysts cut BIOA PTs, keep Buy - TradingViewTradingView · Mon, 03 Aug 2026 11:33:16 GMT